Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90)

Human Molecular Genetics

Volumn 19, Issue 22, 2010, Pages 4421-4436

  Tam, Lawrence C S ^a   Kiang, Anna Sophia ^a   Campbell, Matthew ^a   Keaney, James ^a   Jane Farrar, G ^a   Humphries, Marian M ^a   Kenna, Paul F ^a   Humphries, Pete ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA ACTIN; CASPASE 3; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MUTANT PROTEIN; PERIPHERIN; PROLINE; PROTEIN IMPDH1; RHODOPSIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD RETINA BARRIER; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE; GENE EXPRESSION; GENE MUTATION; HEAT SHOCK; HUMAN; HUMAN CELL; IMPDH1 GENE; MAMMAL CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; RETINITIS PIGMENTOSA; RNA INTERFERENCE; SYSTEMIC THERAPY; VISUAL IMPAIRMENT;

ANIMALS; BENZOQUINONES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GENES, DOMINANT; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMP DEHYDROGENASE; LACTAMS, MACROCYCLIC; MICE; MICE, INBRED C57BL; MUTATION; RETINA; RETINITIS PIGMENTOSA; RHODOPSIN; RNA INTERFERENCE;

MAMMALIA; MURINAE;

EID: 77958483635     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq369     Document Type: Article

References (65)

1. Hartong, D.T., Berson, E.L. and Dryja, T.P. (2006) Retinitis pigmentosa. Lancet, 368, 1795-1809.
2. O'Reilly, M., Palfi, A., Chadderton, N., Millington-Ward, S., Ader, M., Cronin, T., Tuohy, T., Auricchio, A., Hildinger, M., Tivnan, A. et al. (2007) RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet., 81, 127-135.
3. Tam, L.C., Kiang, A.S., Kennan, A., Kenna, P.F., Chadderton, N., Ader, M., Palfi, A., Aherne, A., Ayuso, C., Campbell, M., Reynolds, A. et al. (2008) Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10). Hum. Mol. Genet., 17, 2084-2100.
4. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N. et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med., 358, 2231-2239.
5. Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., Kaushal, S., Schwartz, S.B., Boye, S.L., Windsor, E.A., Conlon, T.J., Sumaroka, A., Pang, J.J. et al. (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther., 20, 999-1004.
6. Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., Mingozzi, F., Bennicelli, J.L., Ying, G.S., Rossi, S. et al. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet, 374, 1597-1605.
7. Dryja, T.P., McGee, T.L., Reichel, E., Hahn, L.B., Cowley, G.S., Yandell, D.W., Sandberg, M.A. and Berson, E.L. (1990) A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature, 343, 364-366.
8. Farrar, G.J., Kenna, P., Jordan, S.A., Kumar-Singh, R., Humphries, M.M., Sharp, E.M., Sheils, D.M. and Humphries, P. (1991) A three-base-pair deletion in the peripherin-RDS gene in one form of retinitis pigmentosa. Nature, 354, 478-480.
9. Kennan, A., Aherne, A., Palfi, A., Humphries, M.M., McKee, A., Stitt, A., Simpson, D.A., Demtroder, K., Orntoft, T., Ayuso, C. et al. (2002) Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho(2/2) mice. Hum. Mol. Genet., 11, 547-557.
10. Bowne, S.J., Sullivan, L.S., Blanton, S.H., Cepko, C.L., Blackshaw, S., Birch, D.G., Hughbanks-Wheaton, D., Heckenlively, J.R. and Daiger, S.P. (2002) Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum. Mol. Genet., 11, 559-568.
11. Mendes, H.F., van der Spuy, J., Chapple, J.P. and Cheetham, M.E. (2005) Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med., 11, 177-185.
12. Illing, M.E., Rajan, R.S., Bence, N.F. and Kopito, R.R. (2002) A rhodopsin mutant linked to autosomal dominant RP is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem., 277, 34150-34160.
13. Saliba, R.S., Munro, P.M., Luthert, P.J. and Cheetham, M.E. (2002) The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J. Cell Sci., 115, 2907-2918.
14. Conley, S.M., Stricker, H.M. and Naash, M.I. (2010) Biochemical analysis of phenotypic diversity associated with mutations in codon 244 of the retinal degeneration slow gene. Biochemistry, 49, 905-911.
15. Aherne, A., Kennan, A., Kenna, P.F., McNally, N., Lloyd, D.G., Alberts, I.L., Kiang, A.S., Humphries, M.M., Ayuso, C., Engel, P.C. et al. (2004) On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Hum. Mol. Genet., 13, 641-650.
16. Olsson, J.E., Gordon, J.W., Pawlyk, B.S., Roof, D., Hayes, A., Molday, R.S., Mukai, S., Cowley, G.S., Berson, E.L. and Dryja, T.P. (1992) Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron, 9, 815-830.
17. Kosmaoglou, M., Schwarz, N., Bett, J.S. and Cheetham, M.E. (2008) Molecular chaperones and photoreceptor function. Prog. Retin. Eye Res., 27, 434-449.
18. Macario, A.J., Grippo, T.M. and de Macario, E.C. (2005) Genetic disorders involving molecular-chaperone genes: a perspective. Genet. Med., 7, 3-12.
19. Hayashi, M., Imanaka-Yoshida, T., Wood, M., Fearns, C., Tatake, R.J. and Lee, J.D. (2006) A crucial role of mitochondria Hsp40 in preventing dilated cardiomyopathy. Nat. Med., 12, 128-132.
20. Stock, A.D., Spallone, P.A., Dennis, T.R., Netski, D., Morris, C.A., Mervis, C.B. and Hobart, H.H. (2003) Heat shock protein 27 gene: chromosomal and molecular location and relationship to Williams syndrome. Am. J. Med. Genet. A., 120A, 320-325.
21. Hidalgo-de-Quintana, J., Evans, R.J., Cheetham, M.E. and van der Spuy, J. (2008) The Leber congenital amaurosis protein AIPL1 functions as part of a chaperone heterocomplex. Invest. Ophthalmol. Vis. Sci., 49, 2878-2887.
22. Parsell, D.A. and Lindquist, S. (1993) The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu. Rev. Genet., 27, 437-96.
23. Pratt, W.B. and Toft, D.O. (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med., 228, 111-133.
24. Mayer, M.P. and Bukau, B. (2005) Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci., 62, 670-684.
25. Young, J.C., Agashe, V.R., Seigers, K. and Hartl, F.U. (2004) Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol., 5, 781-791.
26. Hirayama, S., Yamazaki, Y., Kitamura, A., Oda, Y., Morito, D., Okawa, K., Kimura, H., Cyr, D.M., Kubota, H. and Nagata, K. (2008) MKKS is a centrosome-shuttling protein degraded by disease-causing mutations via CHIP-mediated ubiquitination. Mol. Biol. Cell, 19, 899-911.
27. Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M.K., Hartl, F.U. and Wanker, E.E. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 10, 1307-1315.
28. Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L. and Bonini, N.M. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 23, 425-428.
29. Chan, H.Y., Warrick, J.M., Gray-Board, G.L., Paulson, H.L. and Bonini, N.M. (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet., 9, 2811-2820.
30. Gorbatyuk, M.S., Knox, T., LaVail, M.M., Gorbatyuk, O.S., Noorwez, S.M., Hauswirth, W.W., Lin, J.H., Muzyczka, N. and Lewin, A.S. (2010) Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc. Natl Acad. Sci. USA, 107, 5961-5966.
31. Sloan, L.A., Fillmore, M.C. and Churcher, I. (2009) Small-molecule modulation of cellular chaperones to treat protein misfolding disorders. Curr. Opin. Drug Discov. Dev., 12, 666-681.
32. Harrison, P.J., Procter, A.W., Exworthy, T., Roberts, G.W., Najlerahim, A., Barton, A.J. and Pearson, R.C. (1993) Heat shock protein (hsx70) mRNA expression in human brain: effects of neurodegenerative disease and agonal state. Neuropathol. Appl. Neurobiol., 19, 10-21.
33. Fukuyo, Y., Hunt, C.R. and Horikoshi, N. (2010) Geldanamycin and its anti-cancer activities. Cancer Lett., 290, 24-35.
34. Zou, J., Guo, Y., Guettouche, T., Smith, D.F. and Voellmy, R. (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell, 94, 471-480.
35. Egorin, M.J., Zuhowski, E.G., Rosen, D.M., Sentz, D.L., Covey, J.M. and Eiseman, J.L. (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol., 47, 291-302.
36. Sausville, E.A., Tomaszewski, J.E. and Ivy, P. (2003) Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets, 3, 377-383.
37. Fujikake, N., Nagai, Y., Popiel, H.A., Okamoto, Y., Yamaguchi, M. and Toda, T. (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem., 283, 26188-26189.
38. Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M. and Sobue, G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med., 11, 1088-1095.
39. Mendes, H.F. and Cheetham, M.E. (2008) Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum. Mol. Genet., 17, 3043-3054.
40. Sharp, S. and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res., 95, 323-348.
41. Conchillo-Solé, O., de Groot, N.S., Avilés, F.X., Vendrell, J., Daura, X. and Ventura, S. (2007) AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics, 8, 65.
42. Dehouck, Y., Grosfils, A., Folch, B., Gilis, D., Bogaerts, P. and Rooman, M. (2009) Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0. Bioinformatics, 25, 2537-2543.
43. Fernandes-Alnemri, T., Litwack, G. and Alnemri, E.S. (1994) CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J. Biol. Chem., 269, 30761-30764.
44. Nicholson, D.W., Ali, A., Thornberry, N.A., Vaillancourt, J.P., Ding, C.K., Gallant, M., Gareau, Y., Griffin, P.R., Labelle, M., Lazebnik, Y.A. et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature, 376, 37-43.
45. Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C.B. et al. (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest., 117, 648-658.
46. Campbell, M., Nguyen, A.T., Kiang, A.S., Tam, L.C., Gobbo, O.L., Kerskens, C., Ni Dhubhghaill, S., Humphries, M.M., Farrar, G.J., Kenna
47. P.F. and Humphries, P. (2009) An experimental platform for systemic drug delivery to the retina. Proc. Natl Acad. Sci. USA, 106, 17817-17822.
48. Campbell, M., Kiang, A.S., Kenna, P.F., Kerskens, C., Blau, C., O'Dwyer, L., Tivnan, A., Kelly, J.A., Brankin, B., Farrar, G.J. and Humphries, P. (2008) RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med., 10, 930-947.
49. Ross, C.A. and Poirier, M.A. (2004) Protein aggregation and neurodegenerative disease. Nat. Med., 10, S10-S17.
50. Surguchev, A. and Surguchov, A. (2009) Conformational diseases: Looking into the eyes. Brain Res. Bull., 81, 12-24.
51. Wisniewski, T. and Sadowski, M. (2008) Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci., 9, S5.
52. Herbst, M. and Wanker, E.E. (2007) Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy. Neurodegener. Dis., 4, 254-260.
53. Auluck, P.K. and Bonini, N.M. (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med., 8, 1185-1186.
54. Lu, A., Ran, R., Parmentier-Batteur, S., Nee, A. and Sharp, F.R. (2002) Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J. Neurochem., 81, 355-364.
55. Dobson, C.M. (2002) Getting out of shape. Nature, 418, 729-730.
56. Mortimer, S.E., Xu, D., McGrew, D., Hamaguchi, N., Lim, H.C., Bowne, S.J., Daiger, S.P. and Hedstrom, L. (2008) IMP dehydrogenase type 1 associates with polyribosomes translating rhodopsin mRNA. J. Biol. Chem., 283, 36354-36360.
57. Hay, D.G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D.L., Woodman, B. and Bates, G.P. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 13, 1389-1405.
58. Tokui, K., Adachi, H., Waza, M., Katsuno, M., Minamiyama, M., Doi, H., Tanaka, K., Hamazaki, J., Murata, S. et al. (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet., 18, 898-910.
59. Ramanathan, R.K., Trump, D.L., Eiseman, J.L., Belani, C.P., Agarwala, S.S., Zuhowski, E.G., Lan, J., Potter, D.M., Ivy, S.P., Ramalingam, S. et al. (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res., 11, 3385-3391.
60. Goetz, M.P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A.A., Sloan, J., Atherton, P., Vasile, V. et al. (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol., 23, 1078-1087.
61. Hollingshead, M., Alley, M., Burger, A.M., Borgel, S., Pacula-Cox, C., Fiebig, H.H. and Sausville, E.A. (2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol., 56, 115-125.
62. Shadad, F.N. and Ramanathan, R.K. (2006) 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study. Clin. Lymphoma Myeloma, 6, 500-501.
63. Lancet, J.E., Gojo, I., Burton, M., Quinn, M., Tighe, S.M., Kersey, K., Zhong, Z., Albitar, M.X., Bhalla, K., Hannah, A.L. et al. (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia, 24, 699-705.
64. Wetzler, M., Earp, J.C., Brady, M.T., Keng, M.K. and Jusko, W.J. (2007) Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity-pharmacodynamic drug-drug interaction modeling. Clin. Cancer Res., 13, 2261-2270.
65. Humphries, M.M., Rancourt, D., Farrar, G.J., Kenna, P., Hazel, M., Bush, R.A., Sieving, P.A., Sheils, D.M., McNally, N., Creighton, P. et al. (1997) Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat. Genet., 15, 216-219.